[go: up one dir, main page]

FR2717495B1 - Recombinant viruses, preparation and use in gene therapy. - Google Patents

Recombinant viruses, preparation and use in gene therapy.

Info

Publication number
FR2717495B1
FR2717495B1 FR9403190A FR9403190A FR2717495B1 FR 2717495 B1 FR2717495 B1 FR 2717495B1 FR 9403190 A FR9403190 A FR 9403190A FR 9403190 A FR9403190 A FR 9403190A FR 2717495 B1 FR2717495 B1 FR 2717495B1
Authority
FR
France
Prior art keywords
preparation
gene therapy
recombinant viruses
viruses
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9403190A
Other languages
French (fr)
Other versions
FR2717495A1 (en
Inventor
Laurent Pradier
Pascal Barneoud
Pia Delaere
Michel Perricaudet
Emmanuelle Vigne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Aventis Pharma SA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Rhone Poulenc Rorer SA
Institut Gustave Roussy (IGR)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9403190A priority Critical patent/FR2717495B1/en
Application filed by Centre National de la Recherche Scientifique CNRS, Rhone Poulenc Rorer SA, Institut Gustave Roussy (IGR) filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA002184409A priority patent/CA2184409A1/en
Priority to JP7524416A priority patent/JPH09510357A/en
Priority to EP95911370A priority patent/EP0750675A1/en
Priority to AU18961/95A priority patent/AU1896195A/en
Priority to PCT/FR1995/000249 priority patent/WO1995025803A1/en
Priority to IL112993A priority patent/IL112993A/en
Priority to ZA952242A priority patent/ZA952242B/en
Publication of FR2717495A1 publication Critical patent/FR2717495A1/en
Application granted granted Critical
Publication of FR2717495B1 publication Critical patent/FR2717495B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR9403190A 1994-03-18 1994-03-18 Recombinant viruses, preparation and use in gene therapy. Expired - Fee Related FR2717495B1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR9403190A FR2717495B1 (en) 1994-03-18 1994-03-18 Recombinant viruses, preparation and use in gene therapy.
JP7524416A JPH09510357A (en) 1994-03-18 1995-03-02 Recombinant adenovirus encoding acidic fibroblast growth factor (aFGF)
EP95911370A EP0750675A1 (en) 1994-03-18 1995-03-02 RECOMBINANT ADENOVIRUSES CODING FOR ACIDIC FIBROBLAST GROWTH FACTOR (aFGF)
AU18961/95A AU1896195A (en) 1994-03-18 1995-03-02 Recombinant adenoviruses coding for acidic fibroblast growth factor (afgf)
CA002184409A CA2184409A1 (en) 1994-03-18 1995-03-02 Recombinant adenoviruses coding for acidic fibroblast growth factor (afgf)
PCT/FR1995/000249 WO1995025803A1 (en) 1994-03-18 1995-03-02 RECOMBINANT ADENOVIRUSES CODING FOR ACIDIC FIBROBLAST GROWTH FACTOR (aFGF)
IL112993A IL112993A (en) 1994-03-18 1995-03-14 Recombinant viruses, their preparation and their use in gene therapy
ZA952242A ZA952242B (en) 1994-03-18 1995-03-17 Recombinant viruses their preparation and their use in gene therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403190A FR2717495B1 (en) 1994-03-18 1994-03-18 Recombinant viruses, preparation and use in gene therapy.

Publications (2)

Publication Number Publication Date
FR2717495A1 FR2717495A1 (en) 1995-09-22
FR2717495B1 true FR2717495B1 (en) 1996-04-12

Family

ID=9461189

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9403190A Expired - Fee Related FR2717495B1 (en) 1994-03-18 1994-03-18 Recombinant viruses, preparation and use in gene therapy.

Country Status (8)

Country Link
EP (1) EP0750675A1 (en)
JP (1) JPH09510357A (en)
AU (1) AU1896195A (en)
CA (1) CA2184409A1 (en)
FR (1) FR2717495B1 (en)
IL (1) IL112993A (en)
WO (1) WO1995025803A1 (en)
ZA (1) ZA952242B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2188575A1 (en) 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
FR2792531B1 (en) * 1999-04-26 2003-01-31 Aventis Pharma Sa USE OF DEFECTIVE RECOMBINANT ADENOVIRUS COMPRISING A NUCLEIC ACID ENCODING AN ANGIOGENIC FACTOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
JP2002543097A (en) * 1999-04-26 2002-12-17 アバンテイス・フアルマ・エス・アー Use of a recombinant defective adenovirus containing nucleic acid encoding a pro-angiogenic factor to treat pulmonary arterial hypertension
JP4212357B2 (en) * 2000-11-27 2009-01-21 株式会社ディナベック研究所 Paramyxovirus vectors encoding angiogenic genes and uses thereof
US20070134204A1 (en) * 2005-12-09 2007-06-14 Henrich Cheng Method for treating nerve injury and vector construct for the same
AU2009236960A1 (en) 2008-04-16 2009-10-22 The Chemo-Sero-Therapeutic Research Institute Method of producing thrombin-immobilized bioabsorbable sheet preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2814529B2 (en) * 1989-03-16 1998-10-22 味の素株式会社 Ischemic brain disorder drug
JPH06503962A (en) * 1990-12-18 1994-05-12 アムジエン・インコーポレーテツド Analogs of acidic fibroblast growth factor with enhanced stability and biological activity
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
FR2688514A1 (en) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
NZ256018A (en) * 1992-09-25 1997-07-27 Rhone Poulenc Rorer Sa Recombinant adenoviral vectors and their use in directing expression and transcription of selected nucleotide sequences in cells of the central nervous system
FR2704234B1 (en) * 1993-04-22 1995-07-21 Centre Nat Rech Scient RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY.

Also Published As

Publication number Publication date
JPH09510357A (en) 1997-10-21
IL112993A0 (en) 1995-06-29
AU1896195A (en) 1995-10-09
CA2184409A1 (en) 1995-09-28
ZA952242B (en) 1996-01-09
WO1995025803A1 (en) 1995-09-28
IL112993A (en) 2006-09-05
FR2717495A1 (en) 1995-09-22
EP0750675A1 (en) 1997-01-02

Similar Documents

Publication Publication Date Title
FR2712603B1 (en) Recombinant viruses, preparation and use in gene therapy.
FR2716893B1 (en) Recombinant viruses, their preparation and their therapeutic use.
FR2718150B1 (en) Recombinant viruses, preparation and use in gene therapy.
FR2712602B1 (en) Recombinant viruses, preparation and use in gene therapy.
FI971613A7 (en) Defective adenoviruses comprising a therapeutic gene and an immunoprotective gene
CZ63995A3 (en) Virus vectors and their use in gene therapy
DK0595436T3 (en) PORCINT RESPIRATION AND REPRODUCTION DISEASE VIRUS, VACCINES AND VIRAL DNA
EP0710667A3 (en) Modified oligonucleotides, their preparation and their use
HUP9802217A3 (en) Recombinant mva virus, and the use thereof
FI962990A7 (en) Method for producing recombinant adenovirus-associated viruses (AAVs) and uses thereof
AU3824595A (en) Recombinant negative strand RNA virus expression systems and vaccines
FR2704234B1 (en) RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY.
FI955154A7 (en) Viral recombinants and their use in gene therapy
AU1927797A (en) Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
NO971495D0 (en) Attenuated viruses and processes for their preparation
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
FR2717495B1 (en) Recombinant viruses, preparation and use in gene therapy.
NO974179D0 (en) Recombinant viruses expressing lecithin-cholesterol acyltransferase, and its use in gene therapy
FR2717496B1 (en) Recombinant viruses, preparation and use in gene therapy.
FR2717823B1 (en) Recombinant viruses, preparation and use in gene therapy.
FR2717497B1 (en) Recombinant viruses, preparation and use in gene therapy.
NO902248L (en) PURE-INHIBITING PEPTIDES, THEIR PREPARATION AND USE IN PHARMACEUTICALS.
FR2726575B1 (en) RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY
FI964784L (en) Recombinant DNA viruses, production and use in gene therapy

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20071130